ClinicalTrials.gg
RecruitingNCT07168200Updated Apr 15, 2026

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

A Phase 3 interventional study of SHR-1316 Injection and Cisplatin Injection in Advanced Cervical Cancer, sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
40th of 360
720 · median 90
Started
2025
with 43 others
Phase 3
56 of 455
21 open now
Primary completion
2028-04
later than 205 of 239 live
Registered
419th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 40th largest by planned enrollment of the 360 interventional ones that give a count, is one of 44 that started in 2025, is one of 56 in phase 3, reaches primary completion later than 205 of the 239 other live ones, and was the 419th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

199 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).

03

Conditions studied

  • Advanced Cervical Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participate in the study voluntarily, sign the form.
  2. Subjects were able to provide primary or cancer samples.
  3. At least one .
  4. Expected survival > 3 months.
  5. 0 \~ 1.
  6. With adequate organ functions.

Exclusion criteria

Exclusion Criteria:

  1. Pathologically or radiologically confirmed presence of distant disease, including lymph nodes above the first lumbar vertebra (L1) (cephalad) or in the inguinal region.
  2. Administering within 4 weeks before enrollment or during planned study treatment.
  3. Participants who received therapy within 4 weeks before enrolment.
  4. For participants who are receiving thrombolytic/anticoagulant therapy, prophylactic anticoagulant therapy is allowed.
  5. Participants who have had other uncured malignant tumors in the past (within 5 years) or concurrently have had other uncured malignant tumors, excluding cured basal cell carcinoma of the skin and carcinoma in situ.
  6. Known allergy to the drug or any of its ; or severe allergic reaction to other monoclonal antibodies.
  7. Pregnant or breastfeeding women.
  8. According to the investigator's judgment, there are diseases or any other conditions that may seriously endanger the safety of the subjects, may confound the research results, or affect the subjects' ability to complete the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
720 participants (estimated)

Study arms

  • Experimental
    SHR-1316 Group

    Drug: SHR-1316 Injection · Drug: Cisplatin Injection · Drug: Carboplatin Injection · Drug: Paclitaxel Injection

  • Placebo comparator
    SHR-1316 Placebo Group

    Drug: Cisplatin Injection · Drug: Carboplatin Injection · Drug: Paclitaxel Injection · Drug: SHR-1316 Placebo Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Time frame: Up to approximately 36 months.

Secondary outcomes

  1. Overall survival (OS)

    OS is the time interval from the start of treatment to death due to any reason or lost of follow-up.

    Time frame: Up to approximately 60 months.

  2. 3-year overall survival (OS) rate

    OS rate within 3 years.

    Time frame: Up to approximately 60 months.

  3. 2-year progression-free survival (PFS)

    PFS within 2 years.

    Time frame: Up to approximately 24 months.

  4. Objective Response Rate (ORR)

    Time frame: Up to approximately 36 months.

  5. Duration of response (DoR)

    Time frame: Up to approximately 60 months.

  6. Local recurrence rate

    Time frame: Up to approximately 36 months.

  7. Distant metastasis rate

    Time frame: Up to approximately 60 months.

  8. The second disease progression assessed by the investigator

    Time frame: Up to approximately 60 months.

  9. Adverse events (AEs) including incidence and grade correlation with study drugs

    Time frame: Up to approximately 60 months.

  10. Rate of suspension and discontinuation due to an adverse event correlation with study drugs

    Time frame: Up to approximately 60 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2028, 30 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 30 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 11, 2025
StartActual
Oct 17, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Dec 2028
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07168200
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Oct 17, 2025
Primary completion
Apr 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 15, 2026

Study contacts

Xiaoxu Zhang
Contact
xiaoxu.zhang@hengrui.com
+86-0518-82342973
Zhaoyu Zhong
Contact
zhaoyu.zhong.zz8@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adebrelimab

Start the discussion